載入中
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
前收盤價
US$4.70
+US$0.15 · +3.30%
盤中時間採用ET。市場資料可能有所延遲。
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
日內區間
目前US$4.70
52週區間
目前US$4.70
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
51
合理估值
情緒
42
多空交錯
風險
71
高風險
動能
27
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
日內區間
目前US$4.70
52週區間
目前US$4.70
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 營收 | 285.4萬 USD | 237萬 USD | 238萬 USD | 121.2萬 USD |
| 毛利 | 285.4萬 USD | 237萬 USD | 238萬 USD | 121.2萬 USD |
| 研究與開發 | 1.37億 USD | 6296.6萬 USD | 3179.9萬 USD | 1865.7萬 USD |
| 銷售、一般及管理費用 | 2640.9萬 USD | 1716.8萬 USD | 1069.5萬 USD | 646.4萬 USD |
| 營業費用 | 1.63億 USD | 8013.4萬 USD | 4249.4萬 USD | 2512.1萬 USD |
| 利息收入 | 1693.3萬 USD | 1212.3萬 USD | 416.5萬 USD | 20.5萬 USD |
| 折舊和攤銷 | 18.8萬 USD | 8.9萬 USD | 6萬 USD | 7000 USD |
| 營業利益 | −1.6億 USD | −7776.4萬 USD | −4011.4萬 USD | −2390.9萬 USD |
| 淨利 | −1.43億 USD | −6280.6萬 USD | −2053.7萬 USD | −2386.8萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$25.00
上漲空間 431.91%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI955.28萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM428.28萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF265.22萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO133.91萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Biotechnology ETFIBB127.88萬0.01%108.2億 USD0.44%US$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA95.36萬0.00%218.24億 USD0.03%US$32.79+0.40%
Fidelity Fundamental Small-Mid Cap ETFFFSM76.96萬0.05%14.4億 USD0.43%US$34.13+0.62%
Dimensional - US Small Cap ETFDFAS68.48萬0.00%338.69億 USD0.31%US$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAFidelity Fundamental Small-Mid Cap ETFFFSMDimensional - US Small Cap ETFDFASAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
